Zyprexa Injection Deaths

July 18, 2013

FDA Investigates Zyprexa Injection Deaths


The Food and Drug Administration (FDA) is investigating two unexplained Zyprexa Injection deaths in patients who received an intramuscular injection of the antipsychotic drug Zyprexa Relprevv (olanzapine pamoate).  These patients died 3-4 days after receiving an appropriate dose of Zyprexa Relprevv, well after the 3-hour post-injection monitoring period required under the Zyprexa Relprevv Risk Evaluation and Mitigation Strategy (REMS).

Both Zyprexa Relprevv patients were found to have very high olanzapine blood levels after death. Zyprexa is used for the treatment of aggression, depression, manic episodes, schizophrenia and bipolar disorders. The pill form of the drug lost patent protection in 2011, while the injectable version has no generic competition.

Under the REMS, patients are required to receive the Zyprexa Relprevv injection at a REMS facility, to be monitored at the facility for at least 3 hours following an injection, and to be accompanied home from the facility. The FDA isn’t calling the deaths an overdose, and said the patients had been given an appropriate amount of the drug. Therefore the FDA will be conducting an investigation due to the injectable Zyprexa and deaths resulting.

Zyprexa Injection Death Lawsuit

If you have had a loved one suddenly die after receiving an injection of Zyprexa, then you and your family may be entitled to compensation.  Call the Willis Law Firm for a Free No Fee Case Review. Talk with a Board Certified Personal Injury Trial Lawyer with over 30 years of experience. Call Toll Free 1-800-883-9858

© Willis Law Firm for Drug Attorneys. Replication strictly prohibited without written consent.